Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $239,505.90 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 11,845 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $20.22, for a total value of $239,505.90. Following the completion of the sale, the insider owned 59,992 shares of the company’s stock, valued at $1,213,038.24. The trade was a 16.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Filip Janku also recently made the following trade(s):

• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $21.42, for a total transaction of $642,600.00.

Monte Rosa Therapeutics Stock Up 3.9%

Shares of Monte Rosa Therapeutics stock traded up $0.81 on Thursday, hitting $21.66. The stock had a trading volume of 1,768,259 shares, compared to its average volume of 1,328,242. Monte Rosa Therapeutics, Inc. has a one year low of $4.12 and a one year high of $25.77. The stock’s 50-day simple moving average is $18.79 and its two-hundred day simple moving average is $18.58. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -14.64 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The firm had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. As a group, equities analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Institutional Trading of Monte Rosa Therapeutics

A number of hedge funds have recently modified their holdings of the business. State Street Corp grew its position in shares of Monte Rosa Therapeutics by 148.9% in the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after buying an additional 1,260,707 shares during the period. MPM Bioimpact LLC bought a new stake in Monte Rosa Therapeutics during the fourth quarter worth about $18,399,000. AQR Capital Management LLC grew its holdings in Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after purchasing an additional 1,054,406 shares during the period. Braidwell LP bought a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at approximately $14,870,000. Finally, Vestal Point Capital LP bought a new position in shares of Monte Rosa Therapeutics during the third quarter valued at approximately $5,928,000. Institutional investors own 79.96% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on GLUE shares. Wells Fargo & Company dropped their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. JPMorgan Chase & Co. lifted their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Guggenheim reduced their price target on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Finally, Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.